Antiganglioside antibodies in Guillain-Barre syndrome associated with SARS-CoV-2 infection

alkiviadis.1961 shared this article with you from Inoreader Antiganglioside antibodies in Guillain-Barre syndrome associated with SARS-CoV-2 infection Via Journal of Neurology, Neurosurgery & Psychiatry current issue The pandemic SARS-CoV-2 is dramatically spreading around the world. Patients with COVID-19 typically present with viral pneumonia and resultant life-threatening respiratory complications. Although little information is available regarding the neurological manifestations of COVID-19, there are a few reports that describe Guillain-Barré syndrome (GBS) as an acute presentation of SARS-CoV-2.1 2 Here, we report a new case of COVID-19 initially presenting with acute GBS. On 24 March 2020, a 72-year-old woman arrived at the emergency department of our hospital presenting with lumbar pain, lower limb weakness and paresthesia, which started abruptly and progressed within 2 days (table 1). In the previous 10 days she had fever (Tmax 38.5°C, 101.3°F), anosmia, hypogeusia, dry cough and sore throat lasting for 3 days. Neurological examination disclosed symmetric weakness Medical Research Council (MRC) grade 3/5 in both legs and feet and MRC grade 4/5 in both arms and hands,... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.